BE features a broad range of promising projects in various stages of development. Some of which are highlighted below:
VACCINES IN PIPELINE
Liquid Hexavalent Vaccine : In 2013, GlaxoSmithKline and Biological E partnered to develop liquid hexavalent vaccine. The vaccine comprises of diphtheria, tetanus, whole cell pertussis, inactivated polio, haemophilus influenzae type B and hepatitis B.
Pneumococcal Conjugate Vaccine : Biological E is developing a pneumococcal conjugate vaccine comprising of 13 pneumo serotypes.
Typhoid Conjugate Vaccine : Biological E entered into a technology transfer arrangement with Novartis Vaccine Institute for Global Health (NVGH) in 2013. NVGH had completed Phase 2 trial prior to the technology transfer.
Paratyphoid Vaccine : In addition to the typhoid conjugate vaccine, Novartis Vaccine Institute for Global Health (NVGH) has licensed paratyphoid vaccine technology to Biological E.
Measles Rubella Vaccine : Biological E is developing a measles rubella vaccine. In 2013, Biological E received a commercial grant for this vaccine from Bill and Melinda Gates Foundation.
Inactivated Polio Vaccine : Biological E and Statens Serum Institut (SSI) entered into a technology transfer arrangement for inactivated polio vaccine in 2013 and technology transfer was started immediately. Currently in-house process improvement is being done at Nantes, France.
Inactivated Rotavirus Vaccine : Biological E licensed the technology from Centre for Disease Control and Prevention (CDC) in 2012 and the vaccine is being developed at the company’s facility in Nantes.
Meningitis Vaccine : In 2014, Biological E has started research in order to develop a Men ACWY vaccine.
Biological E respects intellectual property owned by others. Products that are protected under valid patents in respective jurisdictions are not offered or supplied for commercial use. Use of products protected by patent are intended solely for the purpose of Research & Development and for generating data for regulatory submissions.